Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
about
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerCost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United StatesEconomic evaluation research in the context of Child Welfare policy: a structured literature review and recommendationsAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening ProgramsHuman papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis.Epidemiology and costs of cervical cancer screening and cervical dysplasia in ItalyA study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study.Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.Modeling and calibration for exposure to time-varying, modifiable risk factors: the example of smoking behavior in India.The value of improving failures within a cervical cancer screening program: an example from Norway.Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy.Association between physician specialty and uptake of new medical technologies: HPV tests in Florida Medicaid.Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico.Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women.Health and economic implications of HPV vaccination in the United States.Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparitiesOverview of the CDC Cervical Cancer (Cx3) Study: an educational intervention of HPV testing for cervical cancer screeningPrimary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model.HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.The Dynamics of HPV Infection and Cervical Cancer Cells.Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.HPV-DNA testing for cervical cancer precursors: from evidence to clinical practiceAn Efficient, Noniterative Method of Identifying the Cost-Effectiveness FrontierOptimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in AustraliaOptimizing technology for cervical cancer screening in high-resource settings.Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.The detection of hTERC amplification using fluorescence in situ hybridization in the diagnosis and prognosis of cervical intraepithelial neoplasia: a case control study.Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.Evaluating child welfare policies with decision-analytic simulation models.The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation studyMulticohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful informationOverview of methods in economic analyses of behavioral interventions to promote oral healthHuman papillomavirus and vaccination: knowledge, attitudes, and behavioural intention in adolescents and young women in ItalyCalibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial.Parental attitudes and information needs in an adolescent HPV vaccination programmeA comparison between Pap and HPV screening tests and screening methods.
P2860
Q24607403-051C9545-9279-4B8F-B095-CFB37E310C8BQ24655328-F5A06016-DBE2-422A-B9F8-AFF780FCB658Q26824669-4013C808-4AC4-49A8-9CE0-DB5ECE358370Q26828840-84542DE1-4D5D-48E6-AB61-F05A109C957AQ26851181-7C1AC172-957F-4610-8E09-D44F04B91150Q30878077-7647446A-344F-44E3-B380-B1F6516B59B8Q33412571-E3B0AE44-BD30-437F-B8A9-359792C036C1Q33580897-D86B2B05-8CC6-4633-B5B8-DC618B70A7D0Q33708098-434E9C72-430F-489D-92B1-0353B2B64E9CQ33969384-A3AF9218-CE4A-44D0-8B12-32BDDB3E235CQ34021105-CF117439-D85D-45BB-8A91-CC10B23A583AQ34052412-AFB97FDD-08C3-41ED-A001-494D3948B494Q34164287-B6826475-7A9C-4428-93BF-AFD7648E314CQ34250191-8A755412-06A0-438B-B7AE-D91C7437F080Q34511387-2B6CE6F6-91B0-4EA0-8C69-F9C26CA5850DQ34684543-BB7ED254-9B13-4DA2-A066-E537F14FA0CAQ34824304-477CCA23-B43E-488B-B950-AF5BBAE056C0Q35223397-6F9A6F1E-E7AD-452B-AEA1-CC2AC74632BEQ35282197-F1A0FD3F-3B40-44AF-B884-C51658E58F3EQ35802505-DAECDCF3-6465-4E1C-B198-375EEFC1B3D8Q35835143-F3277650-2548-442F-8A8F-E0DCF73E21D6Q35871191-759A8789-185D-42B8-B6FB-D23E35C08B95Q35908482-27F13EE1-297B-4B39-B939-19D98773B6D1Q35927132-D69FC476-09A1-4F74-970F-70F2D4692E36Q36057298-BD376F41-64DB-4CC2-9C87-6712C9D44E7EQ36071760-8A5BC7C0-2558-4981-89A5-97A37029948CQ36225897-578E5D3C-FE68-4159-993D-07B411B61315Q36251151-42B0A400-262B-4E06-871B-881A04D0D6E0Q36319941-BF9A5C96-DE2D-458A-93F3-7C1D445953C8Q36325832-D815743D-F38A-438B-8DEA-69DB8E8759E0Q36360128-B0F4DE89-5662-4636-8C90-3592323E3685Q36371450-4C8E695C-BA1B-4B77-83D3-05DC462C98BFQ36660220-5B57AA05-A18F-4A5F-9FB9-F53199BC4F57Q36699005-B13939D9-C2BA-4FD7-B9AB-92D3D822471EQ36711336-AAF95EF7-EE80-4A1D-9E5D-ECF955EB4A10Q36745358-4C8D6A13-5733-4671-8545-97256F37F9DAQ36786011-6B102CCA-B21F-4D0C-A09A-1410E68E4914Q36843345-CCD768ED-B933-4FF4-B246-4285ED609884Q37010597-21E1A6E7-9CFA-4DD9-B179-0B8D1C304D1FQ37107997-73454C2A-19CC-49F5-AC2F-37D5F70B4671
P2860
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cost-effectiveness of cervical ...... ing and HPV-16,18 vaccination.
@ast
Cost-effectiveness of cervical ...... ing and HPV-16,18 vaccination.
@en
Cost-effectiveness of cervical ...... ing and HPV-16,18 vaccination.
@nl
type
label
Cost-effectiveness of cervical ...... ing and HPV-16,18 vaccination.
@ast
Cost-effectiveness of cervical ...... ing and HPV-16,18 vaccination.
@en
Cost-effectiveness of cervical ...... ing and HPV-16,18 vaccination.
@nl
prefLabel
Cost-effectiveness of cervical ...... ing and HPV-16,18 vaccination.
@ast
Cost-effectiveness of cervical ...... ing and HPV-16,18 vaccination.
@en
Cost-effectiveness of cervical ...... ing and HPV-16,18 vaccination.
@nl
P2860
P50
P356
P1476
Cost-effectiveness of cervical ...... ing and HPV-16,18 vaccination.
@en
P2093
Karen M Kuntz
Natasha K Stout
P2860
P304
P356
10.1093/JNCI/DJN019
P407
P577
2008-02-26T00:00:00Z